ClinicalTrials.gg
CompletedNCT00116844Updated Feb 12, 2018Results posted

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

A Phase 4 interventional study of Valaciclovir and Placebo in Infections, Herpesviridae, sponsored by GlaxoSmithKline. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-12.

Primary conditionHerpes SimplexRegistry: Herpesviridae InfectionsReclassifiedWhy we changed it
Registry
Herpesviridae Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Herpes Simplex
Why
  1. The study's title name Herpes Simplex, a narrower term within Herpesviridae Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2005, registered Jun 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.

Enrollment
5th of 21
73 · median 33
Started
2005
with 1 other
Phase 4
5 of 24
none open now
Registered
9th of 24
by date
Lead sponsor
3 of 24
GlaxoSmithKline

Among the 24 studies testing valacyclovir in Herpes Simplex, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 4, and was the 9th registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing valacyclovir in Herpes Simplex as a file.
02

Study summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

03

Conditions studied

  • Infections, Herpesviridae

Browse trials for

Keywords

  • viral shedding
  • Recurrent
  • herpes
  • genital herpes
04

In context

Herpes Simplex Reclassified

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

This study's enrollment of 73 is above the median of 66 across 113 interventional studies indexed under Herpes Simplex.

Browse Herpes Simplex studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Herpes Simplex, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Herpesviridae Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In overall general good health.
  • HSV-2 (Herpes Simplex Virus-2) seropositive at screening.

Exclusion criteria

Exclusion criteria:

  • have active lesions consistent with genital herpes.
  • previous history of symptomatic genital herpes.
  • history of recurrent, undiagnosed symptoms consistent with genital herpes.
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Sequence 1: VALTREX 1 g once daily, Placebo

    VALTREX 1 g once daily, Placebo

    Drug: Valaciclovir · Drug: Placebo

  • Experimental
    Sequence 2: Placebo, VALTREX 1 g once daily

    Placebo, VALTREX 1 g once daily

    Drug: Valaciclovir · Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2

    Percent of subclinical days with HSV-2 shedding was defined for each participant as the percent of subclinical days with PCR data for which HSV-2 shedding was detected by a positive PCR result, that is, the number of subclinical days with HSV-2 PCR shedding divided by total number of subclinical days with PCR data, multiplied by 100. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or subclinical (no genital lesions). Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

Secondary outcomes

  1. Mean Percent Days of Total HSV-2 Shedding

    The percent of days with total (clinical and subclinical) HSV-2 shedding was defined as the percent of all days with PCR data for which HSV-2 shedding was detected. Mean percent of days with total HSV-2 shedding was the statistic used to summarize this endpoint for each treatment group. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions). The total shedding rate was defined for each participant as the percentage of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

  2. Number of Participants With no Shedding

    The number of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

  3. Mean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding

    The subclinical shedding rate was defined for each participant as the total number of subclinical days on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with subclinical shedding was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all subclinical shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

  4. Mean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding

    The total shedding rate was defined for each participant as the total number of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with total shedding (clinical and subclinical) was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

  5. Percent Overall Study Population Who Have Recognized Clinical Signs/Symptoms of Genital Herpes Infection During the Study

    Participants who have recognized clinical signs/symptoms of genital herpes infection during the study. Participants were educated on recognizing signs and symptoms of genital herpes infection at the screening/randomization visit. Genital examinations was conducted at the randomization and genital herpes outbreak visits.

    Time frame: Up to Day 60 of each treatment period (up to 160 days)

08

Results

Posted Feb 12, 2018

Participant flow

From March-2005 to January-2006, 73 participants from 13 centers in the United States were randomized into the study (36 in VALTREX™-Placebo, and 37 in Placebo-VALTEX treatment sequence). One participant in each treatment sequence did not receive study medication and intent-to-treat exposed (ITTE) population was comprised of 71 participants.

Period 1: Treatment Period 1 (60 Days)
Participant flow — Period 1: Treatment Period 1 (60 Days)
MilestoneSequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once Daily
Started3536
Completed2833
Not completed73
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject50
Withdrew: Other11
Period 2: Washout Period (7 Days)
Participant flow — Period 2: Washout Period (7 Days)
MilestoneSequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once Daily
Started2833
Completed2833
Not completed00
Period 1: Treatment Period 2 (60 Days)
Participant flow — Period 1: Treatment Period 2 (60 Days)
MilestoneSequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once Daily
Started2833
Completed2428
Not completed45
Withdrew: Adverse event10
Withdrew: Lost to follow-up21
Withdrew: Other02
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2

Percent of subclinical days with HSV-2 shedding was defined for each participant as the percent of subclinical days with PCR data for which HSV-2 shedding was detected by a positive PCR result, that is, the number of subclinical days with HSV-2 PCR shedding divided by total number of subclinical days with PCR data, multiplied by 100. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or subclinical (no genital lesions). Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Mean · Percentage of days
Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2
Percentage of daysVALTREX 1 g Once DailyPlacebo
Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-21.5 ± 5.35.1 ± 9
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Nonparametric tests-Wilcoxon Rank Sum · p = <0.001
SecondaryMean Percent Days of Total HSV-2 Shedding

The percent of days with total (clinical and subclinical) HSV-2 shedding was defined as the percent of all days with PCR data for which HSV-2 shedding was detected. Mean percent of days with total HSV-2 shedding was the statistic used to summarize this endpoint for each treatment group. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions). The total shedding rate was defined for each participant as the percentage of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Mean · Percentage of days
Mean Percent Days of Total HSV-2 Shedding
Percentage of daysVALTREX 1 g Once DailyPlacebo
Mean Percent Days of Total HSV-2 Shedding1.5 ± 5.25.5 ± 9.2
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Nonparametric tests-Wilcoxon Rank Sum · p = <0.001
SecondaryNumber of Participants With no Shedding

The number of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Count of participants · Participants
Number of Participants With no Shedding
ParticipantsVALTREX 1 g Once DailyPlacebo
No Shedding4730
Shedding926
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Prescott's method · p = <0.001
SecondaryMean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding

The subclinical shedding rate was defined for each participant as the total number of subclinical days on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with subclinical shedding was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all subclinical shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Mean · DNA copies per day
Mean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding
DNA copies per dayVALTREX 1 g Once DailyPlacebo
Mean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding4.5 ± 0.94.6 ± 0.4
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Nonparametric tests-Wilcoxon Rank Sum · p = 0.800
SecondaryMean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding

The total shedding rate was defined for each participant as the total number of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with total shedding (clinical and subclinical) was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Mean · DNA copies per day
Mean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding
DNA copies per dayVALTREX 1 g Once DailyPlacebo
Mean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding4.5 ± 0.95.2 ± 1.2
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Nonparametric tests-Wilcoxon Rank Sum · p = 0.229
SecondaryPercent Overall Study Population Who Have Recognized Clinical Signs/Symptoms of Genital Herpes Infection During the Study

Participants who have recognized clinical signs/symptoms of genital herpes infection during the study. Participants were educated on recognizing signs and symptoms of genital herpes infection at the screening/randomization visit. Genital examinations was conducted at the randomization and genital herpes outbreak visits.

Time frame:
Up to Day 60 of each treatment period (up to 160 days)
Reported as:
Number · Percentage of participants
Percent Overall Study Population Who Have Recognized Clinical Signs/Symptoms of Genital Herpes Infection During the Study
Percentage of participantsVALTREX 1 g Once DailyPlacebo
No Signs/Symptoms8877
Signs/symptoms Present1323
Statistical analysis
  • VALTREX 1 g Once Daily vs Placebo · Prescott's method · p = 0.0331

Adverse events

Collected over Adverse events (AE) and serious adverse events (SAE) were reported through out the study (up to 160 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valtrex 1 g Once Daily0/65 (0%)0/65 (0%)29/65 (44.6%)
Placebo0/63 (0%)1/63 (1.6%)42/63 (66.7%)
Most frequent serious events
Most frequent serious events
EventValtrex 1 g Once DailyPlacebo
Lower limb fractureInjury, poisoning and procedural complications0/651/63
Loss of consciousnessNervous system disorders0/651/63
Most frequent other events
Showing 10 of 77
Most frequent other events
EventValtrex 1 g Once DailyPlacebo
Upper respiratory tract infectionInfections and infestations2/658/63
NasopharyngitisInfections and infestations2/655/63
HeadacheNervous system disorders3/654/63
DizzinessNervous system disorders4/651/63
Vaginitis bacterialInfections and infestations1/653/63
FolliculitisInfections and infestations0/653/63
ToothacheGastrointestinal disorders0/653/63
NauseaGastrointestinal disorders3/651/63
DiarrhoeaGastrointestinal disorders2/652/63
VomitingGastrointestinal disorders0/652/63

Baseline characteristics

The ITTE population was defined as consisting of all participants who received at least one dose of investigational product and at least one safety and/or efficacy evaluation.

Age, Continuous
Age, Continuous(Years)Sequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once DailyTotal
Mean39.1 ± 12.9635.8 ± 11.6937.4 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once DailyTotal
Female242953
Male11718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: VALTREX 1 g Once Daily, PlaceboSequence 2: Placebo, VALTREX 1 g Once DailyTotal
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American51419
White281947
More than one race112
Unknown or Not Reported101
09

Study locations

17 sites
  • GSK Investigational Site
    Carmichael, California 95608, United States
  • GSK Investigational Site
    Davis, California 95616, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Sacramento, California 92585, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Stony Brook, New York 11794, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84132, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
10

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2005 to primary completion in Jan 2006, 9 months.

Results were first posted in Feb 2018, 12 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 1, 2005
StartActual
Mar 29, 2005
Primary completionActual
Jan 10, 2006
CompletionActual
Jan 10, 2006
Results first posted
Feb 12, 2018
Last update
Feb 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00116844
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 1, 2005
Start date
Mar 29, 2005
Primary completion
Jan 10, 2006
Completion
Jan 10, 2006
Results posted
Feb 12, 2018
Last update
Feb 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion